Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569693 | 0.89 | NMT1 (0.39) | NMT1MCL1WDR5MEP1BLMNA | |
| SCHEMBL21550417 | 0.81 | MEN1 (0.52) | LMNAPOLBL3MBTL1NR3C1PGR | |
| SCHEMBL21569699 | 0.76 | CNR1 (0.43) | WDR5MEP1BLMNAALDH1A1POLB | |
| SCHEMBL9275975 | 0.76 | CA2 (0.40) | MEP1BLMNAALDH1A1CA1CA2 | |
| SCHEMBL21569700 | 0.71 | SMN1; SMN2 (0.50) | NMT1ALDH1A1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL4036882 | 0.70 | MCL1 (0.48) | MCL1LMNAL3MBTL1IDH2CA1 | |
| SCHEMBL16733852 | 0.69 | NMT1 (0.49) | NMT1WDR5ALDH1A1SMN1; SMN2ACLY | |
| SCHEMBL21569866 | 0.68 | AKR1C3 (0.50) | LMNAALDH1A1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL15281769 | 0.68 | KCNN4 (0.38) | LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL21550451 | 0.68 | MEN1 (0.56) | LMNAPOLBL3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136545-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2025-05-01 | — | — | US | claimed |
| WO-2025078308-A1 | GEL FORMULATION FOR TOPICAL OCULAR USE | GLUCOX BIOTECH AB (SE) | 2025-04-17 | — | — | WO | claimed |
| US-12202790-B2 | Sulfonamide derivatives having selective Nox inhibiting activity | GLUCOX BIOTECH AB (SE) | 2025-01-21 | — | — | US | claimed |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2021-06-10 | — | — | US | claimed |
| US-20250136545-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2025-05-01 | — | — | US | disclosed |
| US-12202790-B2 | Sulfonamide derivatives having selective Nox inhibiting activity | GLUCOX BIOTECH AB (SE) | 2025-01-21 | — | — | US | disclosed |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2019215291-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202790-B2 | Sulfonamide derivatives having selective Nox inhibiting activity | NOX4, NOX1, NOX5 | NMT1 727/4885MCL1 2576/4885WDR5 3569/4885 |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | NOX4, NOX1, NOX5 | NMT1 821/4885MCL1 2735/4885WDR5 2958/4885 |
| US-20250136545-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | NOX4, NOX1, NOX5 | NMT1 821/4885MCL1 2735/4885WDR5 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.